Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + R-CHOP Bridging to Auto-HSCT in Extranodal DLBCL
ChiCTR2100053056Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Complete remission rate after 4 cycles. Started Nov 2021; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2100053056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053056.